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Background: The COVID-19 pandemic forced health-related organizations to rapidly
launch country-wide procedures that were easy to use and inexpensive. Body
temperature measurement with non-contact infrared thermometers (NCITs) is among the
most common procedures, both in hospital settings and in many other entities. However,
practical hospital experiences have raised great doubts about the procedure’s validity.
Aim: This study aimed to evaluate the validity of the body temperature measured
using NCITs among oncological and transplant patients who took the polymerase chain
reaction test for SARS-Cov-2 PCR+ and PCR- in a Romanian Hospital.
Methods: Body temperature was measured for 5,231 inpatients using NCITs. The cutoff
point for fever was equal to or above 37.3◦C. Patients then completed a questionnaire
about their symptoms, contact, and travel history.
Findings: Fever was detected in five of 53 persons with PCR+, resulting in a sensitivity
of 9.43% (95% CI, 3.13–20.66%). No fever was verified in 5,131 of 5,171 persons with
PCR-, resulting in a specificity of 99.15% (95% CI, 98.86–99.38%). A defensive vision of
NCIT procedure (maximum standard error only in favor) had a sensitivity of 15.09% (95%
CI, 6.75–27.59%).
Conclusions: The use of NCITs in a triage provides little value for detection of
COVID-19. Moreover, it provides a false sense of protection against the disease while
possibly discriminating individuals that could present fever due to other reasons, such
as oncologic treatments, where fever is a common therapeutical consequence. The
consumption of qualified human resources should be considered, especially in the
context of the shortage of healthcare professionals worldwide.
Keywords: triage, screening, non-contact temperature measurement, COVID-19, SARS-CoV-2
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INTRODUCTION
The infectious disease COVID-19, caused by the SARS-CoV-2
virus, has been widely disseminated globally, with over 40 million
infection cases and over 1.1 million deaths registered during the
pandemic (1). In Romania, 324,094 cases and 8,389 deaths due
to COVID-19 have been reported since the beginning of the
pandemic, that is, from February 26 to November 11, 2020 (1).
During April–August 2020, the monthly average of new cases
varied from 334 in April to 230 in May and 248 in June. Romania
declared a state of emergency (lockdown) on March 16, which
ended onMay 14 but was followed by a state of alert. Themonthly
average of new cases reached 477 in July and 721 in August 2020.
Although the most common symptoms of the disease (fever,
dry cough, and tiredness, among others) are mild (2), it has been
reported that asymptomatic people may be transmission vectors
for the disease. Asymptomatic rates have a broad variability
ranging from 5 to 80% (3).
In Romania, each hospital carries out procedures for
screening, testing, and patient management (Appendix A in
Supplementary Material) based on periodical recommendations
issued by the National Center for Surveillance and Control of
Transmittable Disease (NCSCTB) of the National Institute of
Public Health from Romania (NIPH) (4, 5).
These procedures change according to the pandemic’s
evolution, access to new findings and evidence on symptoms
(including measurement of temperature), travel history, contact
history, and criteria for different categories of patients or medical
personal to qualify for PCR testing. Recommendations by the
Center for Disease Control and Prevention (CDC) and European
Centre for Disease Prevention and Control (ECDC) (6, 7) are
implemented for symptom assessment for COVID-19 in new and
returning patients along with practitioners and visitors, including
the daily measurement of body temperature for all patients in
healthcare settings.
Globally, massive non-contact temperature screening is used
in hospitals, malls, office buildings, airports, and so on,
as a fundamental test in the COVID-19 triage for clinical,
epidemiologic, and other public health reasons. According to
the U.S. Food & Drug Administration (FDA) (8), the normal
body temperature should range between 36.1 to 37.2◦C with the
use of non-contact infrared thermometers (NCITs). However,
the actual behavior of this procedure remains to be proved
in the field. It is imperative to know the extent to which
it is an effective and safe method, or whether it leads to
false clues or bias against patients—particularly in oncology
and transplant patients where fever may occur for multiple
Abbreviations: CDC, Centers for Disease Control and Prevention; CIF,
Clinical Institute Fundeni; EBMT, The European Society for Blood and
Marrow Transplantation; ECDC, European Centre for Disease Prevention and
Control; FDA, U.S. Food & Drug Administration; FN, Febrile Neutropenia;
HCT, Hematopoietic Cell Transplant; HSCT, Hematopoietic Stem Cell
Transplant; CI, Confidence Interval; IVD, In Vitro Diagnostic; NCIT, Non-
contact Infrared Thermometers; NCSCTB, National Center for Surveillance and
Control of Transmittable Disease; NIPH, National Institute of Public Health;
PCR, Polymerase Chain Reaction; RNA, Ribonucleic Acid; UTM, Universal
Transport Medium.
reasons. It must be noted that various factors may influence
measurement of body temperature while screening for fever (e.g.,
environmental conditions, antipyretics, and other respiratory
diseases) (9). For example, there are treatments in oncology
and immunocompromised states that may lead to fever. In
these cases, a positive measurement in patients who visit
oncology/transplant hospitals may be due to a priori fever
associated with their condition, leading to a potentially erroneous
measurement of body temperature. A study in a radiation
oncology center in China, from January to April, identified 27
cases of fever in a total of 770 patients with cancer (10). A
case study of four COVID-19 patients with cancer in China
reported that all of them registered fever 6–36 days after hospital
admission (11). Another study, with a cohort of 138 COVID-
19 inpatients in a Chinese hospital, regardless of cancer status,
reported that 20% of these patients had a fever below 38◦C (12).
One study reported that fever was registered in ∼43% of
COVID patients at the time of admission to hospital and in∼89%
by the time of hospitalization (13). The median duration of fever
in these patients was between 8 and 11 days (14).
In many cancer patients with fever, the symptom could be due
to febrile neutropenia (FN) or even a flu-like syndrome (15).
Cancer patients are at a higher risk of any infection due to
immunosuppression, commonly caused by cancer and cancer-
related treatment. Thus, they are at a higher risk of COVID-19
infection than the general population. Patients receiving active
cancer treatment are at a higher risk than those in remission.
Fever is also a common clinical manifestation in patients
who have had a transplant, as well as for other clinical
reasons not related to COVID-19. Although the purpose of
hematopoietic stem cell transplant (HSCT) is curative, and
the patient could suffer damage if the procedure is delayed,
treatment-related toxicities and technical difficulties would be
amplified and overwhelming during this pandemic. Therefore,
professional societies such as the European Society for Blood
and Marrow Transplantation (EBMT) have issued guidelines
to help physicians during the pandemic. These include sorting
and testing patients (including those without symptoms) before
being admitted to a transplant ward and allocating separate
areas, distinct from the transplant units, for symptomatic patients
awaiting COVID-19 test results. There are also strict rules for
stem cell donors.
Highly immunocompromised pediatric and adult
hematopoietic cell transplant (HCT) recipients frequently
experience respiratory infections caused by viruses that are less
virulent in immunocompetent individuals (16).
Respiratory viral infections in allogeneic HCT recipients
contribute to significant mortality rates ranging between 10 and
50% if the infection progresses to the lower respiratory tract (17).
Another dimension that should be discussed is that fever is a
non-specific, non-sensitive indicator of infection. In developing
countries, infections are the major cause of a fever of unknown
origin (18, 19).
In Romania, each hospital/medical center allocates resources
for screening with questionnaires and body temperature. The
Clinical Institute Fundeni (CIF) is one of the few hospitals in
the country doing PCR tests for all inpatients, in view of its
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specific oncology and transplants profile, and is aligned with
similar hospitals in Europe.
We aim to provide evidence for the low validity of the body
temperature measurement method as it has the possibility of
inducing error and stigmatizing people without COVID-19. This
will allow people infected with COVID-19 to pass through the
triage with a false sense of safety.
The primary objective of this study was to evaluate the
sensitivity of fever measurement with NCITs for positive SARS-
Cov-2 test results that identified the disease in the first PCR+
testing. The secondary objective was to determine the specificity
and accuracy of the fever measurement with NCITs.
METHODS
Setting
The study was conducted at the Clinical Institute Fundeni, a
major referral hospital in Bucharest, the capital city of Romania,
with core competencies on transplant (medullar, liver, renal) and
oncology. The Clinical Institute Fundeni has had an average of
53,060 inpatients in the last 5 years, with more than 80% being
oncological and transplant patients. The study was conducted in
accordance with the Declaration of Helsinki, the protocol was
approved by the Ethics Committee of Clinical Institute Fundeni,
and the patients provided informed consent.
Sample
The sample consisted of 5,231 patients with age ranging from
6 months to 91 years (M = 53.97, SD = 17.95). The sample
included both female (47%) and male (53%) individuals, and was
highly representative (assuming equal probability of fever over
the year), with CI of 95± 1.30% and CI of 99± 1.71%.
All patients tested for SARS-CoV-2 from March 16 to August
30, 2020 were eligible for inclusion. Patients with non-conclusive
PCR in the initial testing were not included (N-3 cases); see
Figure 1. All patients with at least 1 day of hospitalization were
considered. Consultations, visits, or accompanying patients were
excluded from the sample.
Design
This was a consecutive observational study encompassing all
patients admitted to the hospital from March to August 2020.
Procedure
Temperature was measured on the day of admission in the triage
tents placed in front of the hospital entrances with NCITs held at
a distance of one to five centimeters from the skin.
Along with the temperature measurements, a questionnaire
about symptoms, contacts, and travel history was completed
by patients. Data were collected for body temperature at the
time of testing, age, sex, admission department, criteria for
testing measurement, symptoms, contacts, and travel history
(Supplementary Material 1).
In line with the FDA recommendation (8), fever was defined
as a ≥37.3◦C body temperature.
The triage data recording system included a handwritten
paper registry completed by the triage teams, trained and
designated by the hospital.
After the triage, all admitted patients were allocated to one of
three zones according to the triage’s findings for nose and throat
swabs—green (no findings for COVID-19), yellow (suspicions
for COVID-19), or red (possibly positive for COVID-19).
Testing of nose and throat swab samples was performed using
a quantitative reverse-transcription polymerase chain reaction in
the CIF laboratory.
Nasal and oropharyngeal samples from patients to be
hospitalized at the Fundeni Clinical Institute were collected
within a single tube of universal transport medium (UTM R©;
Copan Italia S.p.A., Brescia, Italy) to prevent viral RNA
degradation and bacterial/fungal overgrowth. Briefly, 200 µl of
the sample was processed with a Seegene Nimbus automated
system, which performs both RNA extraction–using STARMag
96 × 4 Viral DNA/RNA 200C Kit—and PCR assay setup.
The RNA isolation procedure comprised four steps: sample
lysis, binding nucleic acid to magnetic beads, washing debris,
and purified nucleic acid elution. The Allplex 2019-nCoV
Assay (Seegene, Seoul, South Korea) is an in vitro diagnostic
(IVD) real-time reverse transcriptase-polymerase chain reaction
(RT-PCR) assay developed for the detection of the nucleic
acids in human samples from individuals with symptoms
of severe acute respiratory syndrome related to coronavirus
2 (SARS-CoV-2). This assay was designed for amplifying
three viral targets: the E gene (specific to the subgenus
Sarbecovirus), as well as the N and the RdRP genes (both
specific to SARS-CoV-2) (20). The tube PCR strips with
the extracted RNA was loaded onto a real-time PCR C1000
CFX96 Thermal Cycler (Bio-Rad Laboratories, Hercules, CA,
USA). Positive and negative controls were included in each
run. After completion of the assay, the Seegene Viewer 2019-
nCoV software allowed automated analysis and interpretation
of results.
After receiving the PCR results, the patient was finally
allocated to the department’s red or green zone. Data from
the laboratory were available in an Excel format. Two
resident doctors worked for 2 months to manually match
registered temperatures with PCR results in the Microsoft
Excel software.
Quantitative Analysis Tools
Results were reported using proportions with 95% confidence
intervals. All analyses were conducted with SPSS version
25. Calibration is not necessary for the devices mentioned,
eliminating the need to include the calculation or the calibration
error or to verify the calibration date and accreditation of the
calibrating entity. The devices used are authorized for operation
without calibration, and certified for medical or private use for
measuring human or animal temperature by the FDA (Certificate
of conformity number 3015697152), European Metrology (CE)
(Certificate of compliance number 4M200326.SZTDD37), and
ISO13485: 2016 (Certificate of compliance number TW50598U,
issued on April 8, 2019).
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FIGURE 1 | Patients selection.
RESULTS
Of the 5,231 individuals, 49 tested positive for fever (fever +),
and 53 were PCR +. Three PCR tests were inconclusive, and
the remaining 5,175 were negative. For fever or PCR, there was
no significant difference between males and females. Out of the
53 PCR + cases, five registered a fever, but 48 did not. Out of
the 5,175 PCR—cases, 44 registered a fever (Figure 1). Sensitivity
9.43%, 95% CI (3.13–20.66%). Specificity 99.15% 95% CI (98.86–
99.38%). Accuracy 98.25%, 95% CI (97.86–98.59%). Fisher exact
<0.001. Disease prevalence 1.00%.
DISCUSSION
A sensitivity value of 9.5% at the first testing of PCR+ is
considered to be extremely low. This means that a significant
number of SARS-CoV-2 patients would pass through the
temperature triage and be admitted to the hospital as negative
when, in fact, they would be positive—suggesting the possibility
of a large number of false negatives. Consequently, the effort and
cost of mobilizing staff to measure temperatures at the entrance
increase all nosocomial risks since more than 90% of people
with COVID-19 end up proceeding with the clinical process. The
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value of this NCITmethod for the daily assessment of COVID-19
inpatients was not evaluated.
Our findings suggest that 48 patients, representing 90.5% of
PCR + patients (1—sensitivity), were false negatives. Patients
were admitted to a green, yellow, or red zone of the department,
following triage findings based on symptoms, history, contact,
and temperature. The internal code for this procedure was PO-
MED-40. The PCR was performed within 6–24 h, depending on
the status of the medical emergency. The hospital also conducted
the PCR on all admitted patients, even those who did not fulfill
the criteria (289 of 5,321).
Specificity value was found to be very high, reaching 99.15%.
Nonetheless, 44 patients out of 5,228 were false positive (1—
specificity). This implies delay in medical services for these
patients, at least until the PCR tests were conducted.
It must be noted that no calculation was done for the whole
hospital triage scheme in place, which also included questions
about contact, symptoms, and travel history. The results may vary
if these questions are added to the temperature triage. The cut-off
point of 37.3◦C considered for fever was another concern.
Our findings are consistent with the previous literature (21,
22). A study in an Australian hospital concluded that fever
screening lacked sensitivity to detect patients with SARS-CoV-
2 (23). In another study set in a hospital, out of 40,887 patients
who attended health services, fever was detected in five patients
on the outdoor triage and in 37 patients in the indoor clinic zone
after being acclimatized (24). Therefore, screening for fever in
Taiwan hospitals needs to be reinforced, with body temperature
measured in two separate time slots and zones (24), allowing
for acclimatization to each environment, which could otherwise
mask the presence of fever. This was considered an important
step to reduce the risk of admitting individuals with a fever that
was not detected at the first screening.
Although body temperature measurement provides some help
in identifying patients with COVID-19, its use involves some risk,
as follows:
• The vast majority of PCR + cases are not identified. Besides
providing a false sense of security, people who are not infected
are set in the same space as those who are infected, possibly
for hours.
• Most people who are referred to the red zone are false
positives, generating stigmatization and great anxiety in most
cases, which are harmful for patients who are already fragile
due to their condition.
• We suggest studying screening alternatives other than NCITs
in the context of COVID-19. Once the resistance to rapid
testing based on the most recent bibliography (about the
generation of false negatives) is overcome, use of rapid PCR
is a possibility. Although its safety level is lower than that of
serologic tests, it is much more sensitive than screening based
on body temperature measurement.
For future research directions, it would be interesting to use the
same assessment to verify whether fevers, false positives, and
false negatives occur in other types of hospital services with the
same density as they do in cancer and transplant hospitals. We
estimate the probability of fever results directly from concrete
phases of treatment, as well as with the type of cancer. However,
it would be important to verify and study patients who should
always be excluded from this type of procedure. Recognizing
that there is no reliable method, it would be interesting to
compare the validity of fever measurement, with or without
insertion in a broader protocol, by using rapid PCR tests in
another sample. Finally, we believe it is of the utmost importance
to complement this work with an economic study involving
the direct and indirect costs of this procedure. Costs include
labor, use of space and equipment, and, in particular, risk of
contagion outbreaks in the hospital from unidentified COVID-
19 cases.
CONCLUSION
Our findings indicate that testing for fever with NCITs has a
very low sensitivity to COVID-19, thus questioning NCIT use for
fever screening. The issue is not about the utility of the device (for
metrological reading) but its use in clinical testing procedures
(patient safety reading).
Not only is the usefulness of NCIT-based testing open to
question, but it might induce a false sense of security while
reducing the patient’s effective safety in hospital settings as it
allows passage of COVID-19 patients. It also diverts attention
from public health measures that are more likely to be effective
uses of resources, such as self-isolation when ill, physical
distancing, mask-wearing, and contact tracing.
the context of the severe shortage of qualified personnel
to respond to needs of the growing number of cases in the
pandemic while catering to the demands of the current healthcare
setting, the fever-screening procedure increases financial costs
and personnel allocation needs with no apparent gain.
Therefore, we recommend that body temperature
measurement be eliminated from hospital admission procedures,
especially in oncological hospitals or other hospitals with high
immunological impairment.
A possible alternative solution for screening patients for
admission to hospital could be rapid low-cost testing for
a first triage while serological PCR results are determined.
It also allows for a quick response to the circulation of
people within the hospital with a greater degree of safety
than currently verified.
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